| Disease Area |
Status |
Protocol |
Sponsor |
Drug Name |
| Gonorrhea |
Enrolling |
A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae |
GSK |
Gepotidacin |
| HBV |
Enrolling |
A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection |
Janssen |
JNJ-73763989 and/or JNJ-56136379 and/or other Regimens |
| HBV |
Ongoing |
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistenct of Sci-B-Vac in Adults (CONSTANT) |
VBI |
Sci-B-Vac |
| HCV |
Ongoing |
An Open-Label, Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II). |
N/A |
ABT-450/ABT-267/ABT-333 |
| HCV |
Ongoing |
Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Sponsored Trials |
Gilead |
N/A |
| HDV |
Enrolling |
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR) |
Eiger |
50MG Lonafarnib/100MG Ritonavibid |
| HIV |
Complete |
A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF. |
Gilead |
Emtricitabine/Tenofovir Alafenamide |
| HIV |
Complete |
A Phase 3, randomized, active-controlled, open-label study to evaluate the efficacy, safety and tolerability of switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically-suppressed, human immunodeficiency virus type 1 (HIV-1) infected subjects. |
Janssen |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide |
| HIV |
Complete |
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects. |
MERCK |
MK-1439/3TC/TDF Single Tablet |
| HIV |
Complete |
“A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combination regimen versus a regimen consisting of darunavir/cobicistat fixed dose combination coadministered with emtricitabine/tenofovir disoproxil fumarate fixed dose combination in antiretroviral treatment-naïve human immunodeficiency virus type 1 infected subjects.” |
Janssen |
D/C/F/TAF (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) |
| HIV |
Enrolling |
Study to Evaluate the Safety and Efficacy of GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV (CALIBRATE) |
Gilead |
GS-6207 |
| HIV |
Enrolling |
A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance |
Gilead |
GS-6207 |
| HIV |
Enrolling |
A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once- Daily in HIV-1 Infected Treatment-Naïve Participants |
Merck |
|
| HIV |
Ongoing |
A Phase III, randomized, multicenter, parallel-group, non-inferiority open-label study evaluating the efficacy, safety and tolerability of switching to long-acting cabotegravir plus long-acting rilpiverine from current INI-, NNRTI- or PI-based antiretroviral regimen in HIV 1 infected adults who are virologically suppressed |
GSK/ViiV Healthcare |
GSK1265744 |
| HIV |
Ongoing |
A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir plus lamivudine in HIV 1 infected adults who are virologically suppressed |
GSK/ViiV Healthcare |
|
| HIV |
Ongoing |
A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults who are Virologically Suppressed |
GSK/ViiV Healthcare |
GSK1265744 |
| HIV |
Ongoing |
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults |
Gilead |
GS-9883/F/TAF |
| HIV |
Ongoing |
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults |
Gilead |
GS-9883/F/TAF |
| HIV |
Ongoing |
A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection |
Gilead |
F/TAF |
| HIV |
Ongoing |
A Phase III, Randomized, Multicenter, Parallel-group, Open- Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants |
GSK/ViiV Healthcare |
GSK1265744 |
| HIV |
Ongoing |
Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults |
Gilead |
GS-6207 |
| HIV |
Ongoing |
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects who are Virologically Suppressed |
Gilead |
Biktegravir |
| NASH |
Complete |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis |
Gilead |
Selonsertib (SEL; GS-4997) |
| NASH |
Complete |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) |
Gilead |
Selonsertib (SEL; GS-4997) |
| NASH |
Enrolling |
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis |
Tobira |
Cenicriviroc mesylate (CVC) |
| NASH |
Enrolling |
A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation |
Madrigal |
Resmetirom |
| NASH |
Enrolling |
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of AKR-001 in Subjects With Nonalcoholic Steatohepatitis (NASH) |
Akero |
AKR-001 |
| NASH |
Enrolling |
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects with Nonalcoholic Steatohepatitis (NASH) |
Gilead |
Multiple |
| NASH |
Enrolling |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis |
Gilead |
GS-9674 |
| NASH |
Enrolling |
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of NGM282 Administered for 24 Weeks for the Treatment of Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) |
NGM |
NGM282 |
| PBC |
Enrolling |
A 5-year Longitudinal Observational Study of Patients with Primary Biliary Cholangitis |
Target PharmaSolutions |
none/observational |
|
Enrolling |
A Phase 1b Randomized, Blinded, Placebo-Controlled, Staggered, Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-9722, Administered Alone or in Combination with Vesatolimod, in Virologically Suppressed HIV-1 Infected Subjects on ART |
Gilead |
|
